Abstracts tagged "Osteoarthritis"

Abstract Number: 978 • 2014 ACR/ARHP Annual Meeting
Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis
Rebecca J. Cleveland¹, Jordan B. Renner², Joanne M. Jordan³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Department of Radiology, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose The determinants of disability progression (DP) among those with knee and/or hip osteoarthritis (OA) are not well known. Our aim was to explore whether…
Abstract Number: 2233 • 2014 ACR/ARHP Annual Meeting
A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis
Juergen Rech¹, Francesca Faustini¹, Axel J. Hueber¹, Wolfgang Ochs², Wolfgang Spieler³, Herbert Kellner⁴, Ulf Muller-Ladner⁵, Mathias Grünke⁶, Matthias Schneider⁷ and Georg Schett⁸, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatologist in private practice, Bayreuth, Germany, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ⁵Internal Medicine/Rheumatology, Univ Giessen/Kerckhoff-Clinic, Bad Nauheim, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose We report on a phase II, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study in subjects with erosive hand osteoarthritis. Subjects must have had…
Abstract Number: 922 • 2014 ACR/ARHP Annual Meeting
A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain
Rachel E. Miller¹, Shingo Ishihara², Phuong Tran³, Richard J. Miller⁴ and Anne-Marie Malfait⁵, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁵Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose - Damage associated molecular patterns (DAMPs) result from cellular stress and extracellular matrix breakdown. They may contribute to osteoarthritis (OA) pathogenesis by promoting synovitis…
Abstract Number: 2237 • 2014 ACR/ARHP Annual Meeting
Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients
Susanne X. Wang¹, Jeroen Medema¹, Matthew Kosloski¹, Wei Liu¹, Mary Saltarelli¹ and Morten Asser Karsdal², ¹AbbVie Inc., North Chicago, IL, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) may comprise multiple phenotypes, one of which is inflammation-driven OA. Consequently, a selected subpopulation of OA patients may benefit from optimally targeted…
Abstract Number: 257 • 2014 ACR/ARHP Annual Meeting
Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia
Karine Briot¹, Hélène Ché¹, Adrien Etcheto¹, Anya Rothenbuhler², Peter Kamenicky,², Agnès Linglart² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hôpital Bicêtre, Kremlin Bicêtre, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: X-Linked Hypophosphatemia (XLH) is the most common form of heritable rickets. Although disease severity is variable, adults with XLH may suffer from skeletal symptoms…
Abstract Number: 2243 • 2014 ACR/ARHP Annual Meeting
Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?
Giuseppa Quartarone¹ and Nathalie Hasler-Nguyen², ¹Medical Affairs, Novartis CH R&D OU Italy Greece, Milan, Italy, ²Pre-Cinical Development, Novartis CH Global R&D, Nyon, Switzerland
Background/Purpose Topically applied non-steroidal anti-inflammatory drugs (NSAIDs) can produce clinically effective drug concentrations at a peripheral site, but with low systemic concentrations and thus a…
Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting
A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes
Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
Abstract Number: 2247 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss
Christopher Chong¹, Sangeeta Kashyap², Philip Schauer², Colin O'Rourke³ and M. Elaine Husni⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, JJN3-01, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Numerous studies support obesity as a strong risk factor for development and progression of knee osteoarthritis (OA). The potential benefits of massive weight loss,…
Abstract Number: 222 • 2014 ACR/ARHP Annual Meeting
OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing…
Abstract Number: 2141 • 2014 ACR/ARHP Annual Meeting
Sensitivity to Change of Joint Space Width Measurements in Hand Osteoarthritis in a Two Year Follow-up Study
W. Damman¹, S.E. de Bruin¹, B.C. Stoel², R. van 't Klooster² and M. Kloppenburg¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cartilage loss, represented by joint space width (JSW) on radiographs, is an important outcome measure in hand OA disease course. JSW can be assessed…
Abstract Number: 219 • 2014 ACR/ARHP Annual Meeting
DXA Body Composition, Sarcopenia and Knee and Hip Osteoarthritis: Results from the Khoala Cohort
Clémence Jeanmaire¹, Isabelle Chary-Valkenaere¹, Damien Loeuille², Lorraine Bernard³ and Anne-Christine Rat,⁴, ¹Rheumatology, CHU Nancy, Vandoeuvre Les Nancy, France, ²Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ³CHU Nancy, Pôle S2R, Epidémiologie et Evaluation Cliniques, INSERM, CIC-EC, CIE6, Vandoeuvre Les Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; Inserm, , CIC-EC, CIC 1433, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France
Background/Purpose Obesity is a well known risk factor for the development and progression of knee osteoarthritis (OA), and to a lesser extent of hip OA.…
Abstract Number: 1969 • 2014 ACR/ARHP Annual Meeting
Neurotrophin Receptor p75 (CD271) Defines a Distinct Synovial Fibroblast Subset in Rheumatoid and Osteoarthritic Synovial Tissues with Enhanced Proinflammatory Potential
Manuel J. Del Rey¹, Regina Faré¹, Gabriel Criado², Alicia Usategui¹, Vanessa Miranda¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose Synovial mesenchynmal or stromal cells constitute a heterogeneous cell population difficult to characterize ex vivo due to a paucity of cell markers and are…
Abstract Number: 207 • 2014 ACR/ARHP Annual Meeting
Changes in Knee Compartment Distriubtion of Cartilage Loss and Bone Marrow Lesions over 7 Years: The MOST Study
Joshua Stefanik¹, Ali Guermazi², Jingbo Niu³, Frank Roemer⁴, C.E. Lewis⁵, Neil A. Segal⁶, Michael Nevitt⁷ and David T. Felson⁸, ¹Clinical Epidemiology, Boston University, Boston, MA, ²Radiology, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ⁴Klinikum Augsburg, Augsburg, Germany, ⁵University of Alabama at Birmingham, Birmingham City, AL, ⁶Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁷Epidemiology and Biostatistics, UCSF, San Francisco, CA, ⁸Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Knee osteoarthritis (OA) occurs in both the patellofemoral joint (PFJ) and tibiofemoral joint (TFJ). Little is known about the natural history of OA and…
Abstract Number: 1820 • 2014 ACR/ARHP Annual Meeting
Discordance of Hip Pain with Radiographic Hip Osteoarthritis: The Osteoarthritis Initiative
Chan Kim¹, Michael C. Nevitt², Pia M. Jungmann³, Irina Tolstykh⁴, Nancy E. Lane⁵, Thomas M. Link⁶ and David T. Felson⁷, ¹Rheumatology, Boston University, Boston, MA, ²Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ³Radiology, Technische Universitaet Muenchen, Munich, Germany, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, ⁶Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁷Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
Background/Purpose It is assumed that persons with hip pain from osteoarthritis (OA) are likely to have radiographic OA, making it possible to readily diagnose disease,…
Abstract Number: 200 • 2014 ACR/ARHP Annual Meeting
Leg Length Inequality and Hip Osteoarthritis
Chan Kim¹, Jingbo Niu², Mary Clancy³, Ali Guermazi⁴, Michael C. Nevitt⁵, Neil A. Segal⁶, William F. Harvey⁷, Cora E Lewis⁸ and David T. Felson⁹, ¹Rheumatology, Boston University, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ³Clinical Epidemiology, Boston University Sch Med, Boston, MA, ⁴Radiology, Boston University School of Medicine, Boston, MA, ⁵Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁶Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, ⁷Rheumatology, Tufts Medical Center, Boston, MA, ⁸Division of Preventive Medicine, University of Alabama Birmingham School of Medicine, Birmingham, AL, ⁹Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
Background/Purpose Leg length inequality (LLI), a side-to-side difference in lower limb lengths, is common. In the Multicenter Osteoarthritis Study (MOST), in persons with LLI, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].